Riskpilot← Back to searchSign inGet full accessBiotech-IgG International AB
ABBankruptOrg 5593193625Research and experimental development on natural sciences and engineering · NACE 7210Est. 20210 employees
Revenue 2023
SEK 0
EBITDA margin
—
+96% vs 2022
Equity ratio
19.5%
Financial strength
Net profit 2023
SEK -6K
+95% vs 2022
| Revenue | SEK 0 | — |
| EBITDA | SEK -4K | +96% |
| Net profit | SEK -6K | +95% |
| Total assets | SEK 221K | +16% |
| Equity | SEK 43K | -12% |
| Employees | 0 | — |
Legal name
Biotech-IgG International AB
Org number
5593193625
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
26 maj 2021
Share capital
SEK 25 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2023-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska bedriva managementverksamhet, produktförsäljning, e-handel och varumärkeshantering. Bolaget ska även bedriva förvaltningsverksamhet genom att direkt eller indirekt förvärva, förmedla och avyttra aktier och andelar i syfte att skapa värde- tillväxt för bolagets ägare. Bolaget ska även kunna bedriva med ovanstående verksamheter förenlig verksamhet.
Address
Email
jesper@starander.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Staff expenses | — | — | — |
| EBITDA | −8 | −118 | −4 |
| Depreciation & amort. | −0 | — | — |
| EBIT | −8 | −118 | −4 |
| Net financials | — | −0 | −1 |
| Profit before tax | −8 | −118 | −6 |
| Tax | −0 | — | — |
| Net profit | −8 | −118 | −6 |
| Item | 2021 | 2022 | 2023 |
|---|---|---|---|
| Total assets | 86 | 191 | 221 |
| Equity | 17 | 49 | 43 |
| Long-term debt | 0 | — | — |
| Short-term debt | 69 | 142 | 178 |
| Total debt | 69 | 142 | 178 |
EBITDA margin
-446400.0%
This company
15.8%
Market median
-2825416% vs market
20212023
Equity ratio
19.5%
This company
38.2%
Market median
-49% vs market
20212023
Return on equity
-13.5%
This company
18.4%
Market median
-173% vs market
20212023
Net profit margin
-584700.0%
This company
8.1%
Market median
-7218619% vs market
20212023
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212023
Debt / equity
4.13×
This company
0.62×
Market median
-566% vs market
20212023
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2024 | |
| Board of Directors | 2024 | |
| Former (6) | ||
| Deputy Board Member | 2022 – 2024 | |
| Board of Directors | 2021 – 2022 | |
| Board of Directors | 2022 – 2024 | |
| Deputy Board Member | 2022 – 2022 | |
| Board of Directors | 2022 – 2022 | |
| Deputy Board Member | 2021 – 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Biotech-IgG Equity AB (publ)
Biotech-IgG International AB Board members of Biotech-IgG International AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Johan Karl-Herbert Lee Backman | Deputy Board Member | 0 companies |
| David Glavonjic | Board of Directors | 0 companies |
| Hugo Glenn Renhult | Board of Directors | 0 companies |
| Olof Ludvig Emanuel Weström | Deputy Board Member | 0 companies |
| Ulf Samuel Melker Törnqvist | Board of Directors | 0 companies |
| Anna Sofie Starander | Deputy Board Member | 0 companies |
| Jessica Margareta Efeoglu Nittsjö | Deputy Board Member | 0 companies |
| Bo Jesper Starander | Board of Directors | 0 companies |